13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
104 檔
20.2%
According to the latest 13F quarterly dataset, Orbimed Advisors LLC managed an equity portfolio of $5.4B at the end of Q3 2025, spanning 104 distinct U.S. exchange-listed positions.
Orbimed Advisors LLC executed strategic sector rebalancing during Q3 2025, establishing 32 new positions while fully exiting 35 holdings and trimming 28 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BSX | Boston Scientific CORP | Stock-Healthcare | 6.03% | -1.88% | -6.54% | |
| 2 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.92% | +1.73% | — | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.40% | +1.30% | -10.78% | |
| 4 | SVA | Sinovac Biotech Ltd. | Stock-Other | 4.33% | +3.06% | — | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.83% | +0.02% | — | |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.23% | -0.71% | -11.79% | |
| 7 | SYK | Stryker CORP | Stock-Healthcare | 3.12% | -0.30% | — | |
| 8 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 3.08% | -0.61% | -1.41% | |
| 9 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.02% | -0.80% | -1.31% | |
| 10 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.99% | -0.44% | -17.16% | |
| 11 | SION | Sionna Therapeutics Inc | Stock-Other | 2.56% | -0.80% | — | |
| 12 | UPB | Upstream Bio Inc | Stock-Other | 2.52% | -0.32% | — | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 2.20% | -0.91% | — | |
| 14 | CAI | Caris Life Sciences Inc | Stock-Other | 2.16% | -0.10% | — | |
| 15 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.96% | -0.12% | — | |
| 16 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.68% | — | -9.60% | |
| 17 | MBX | Mbx Biosciences Inc | Stock-Other | 1.65% | +1.30% | — | |
| 18 | CGON | Cg Oncology Inc | Stock-Other | 1.63% | -0.03% | -14.84% | |
| 19 | NTRA | Natera Inc | Stock-Healthcare | 1.62% | +0.26% | -27.66% | |
| 20 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.52% | -0.20% | +24.28% | |
| 21 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.37% | — | +67.94% | |
| 22 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.33% | — | — | |
| 23 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.31% | +0.53% | — | |
| 24 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.31% | -0.08% | +93.27% | |
| 25 | EXK | Exact Sciences CORP | Stock-Materials | 1.28% | — | +63.77% | |
| 26 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.25% | -1.03% | — | |
| 27 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 1.24% | -0.16% | — | |
| 28 | DHR | Danaher CORP | Stock-Healthcare | 1.23% | -1.03% | EXIT | |
| 29 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.17% | -0.04% | +4.35% | |
| 30 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.17% | — | -19.36% | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.13% | — | — | |
| 32 | CI | THE Cigna Group | Stock-Healthcare | 1.10% | — | — | |
| 33 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.03% | -0.29% | +304.96% | |
| 34 | JANX | Janux Therapeutics Inc | Stock-Other | 1.01% | -0.13% | +45.92% | |
| 35 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.97% | — | -2.33% | |
| 36 | ASND | Ascendis Pharma A/S | Stock-Other | 0.90% | -0.85% | EXIT | |
| 37 | SIBN | Si-bone Inc | Stock-Other | 0.89% | — | — | |
| 38 | SCPH | Scpharmaceuticals Inc | Stock-Other | 0.81% | — | — | |
| 39 | ABVX | Abivax Sa-adr | Stock-Other | 0.76% | +0.79% | — | |
| 40 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.75% | +0.75% | -5.00% | |
| 41 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.71% | -0.10% | — | |
| 42 | ITGR | Integer Holdings CORP | Stock-Healthcare | 0.70% | — | -33.09% | |
| 43 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.69% | +0.26% | +124.37% | |
| 44 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.66% | — | -33.82% | |
| 45 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 46 | NPCE | Neuropace Inc | Stock-Other | 0.63% | -0.11% | — | |
| 47 | QURE | uniQure N.V. | Stock-Other | 0.63% | +0.83% | — | |
| 48 | EYPT | Eyepoint Inc | Stock-Other | 0.60% | — | — | |
| 49 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.59% | — | +149.03% | |
| 50 | ✓ | Adc Therapeutics SA | Stock-Other | 0.56% | -0.10% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UPB | Upstream Bio Inc | +1.7% | — | Unchanged |
| 2 | SION | Sionna Therapeutics Inc | +1.6% | — | Unchanged |
| 3 | ALNY | Alnylam Pharmaceuticals Inc | +1% | -11.79% | Trim |
| 4 | MBX | Mbx Biosciences Inc | +1% | — | Unchanged |
| 5 | ORIC | Oric Pharmaceuticals Inc | +0.9% | +304.96% | Add |
| 6 | 430 | Terns Pharmaceuticals Inc | +0.8% | — | Unchanged |
| 7 | CRVS | Corvus Pharmaceuticals Inc | +0.7% | — | Add |
| 8 | APLSUSD | Apellis Pharmaceuticals Inc | +0.6% | +67.94% | Add |
| 9 | EXK | Exact Sciences CORP | +0.6% | +63.77% | Add |
| 10 | TRVI | Trevi Therapeutics Inc | +0.5% | — | Add |
| 11 | IRON | Disc Medicine Inc | +0.5% | — | Unchanged |
| 12 | JANX | Janux Therapeutics Inc | +0.5% | +45.92% | Add |
| 13 | AXSM | Axsome Therapeutics Inc | +0.4% | +24.28% | Add |
| 14 | DYN | Dyne Therapeutics Inc | +0.4% | +124.37% | Add |
| 15 | EW | Edwards Lifesciences CORP | +0.4% | -1.41% | Add |
| 16 | SCPH | Scpharmaceuticals Inc | +0.4% | — | Unchanged |
| 17 | GPCR | Structure Therapeutics Inc | +0.4% | -5.00% | Add |
| 18 | AKRO | Akero Therapeutics Inc | +0.4% | +149.03% | Add |
| 19 | RNAGBP | Avidity Biosciences Inc | +0.4% | -9.60% | Trim |
| 20 | CRNX | Crinetics Pharmaceuticals In | +0.4% | +4.35% | Add |
| 21 | ✓ | Adc Therapeutics SA | +0.4% | — | Trim |
| 22 | KRYS | Krystal Biotech Inc | +0.3% | +1016.79% | Add |
| 23 | FBRX | Forte Biosciences Inc | +0.3% | — | Add |
| 24 | CMPX | Compass Therapeutics Inc | +0.2% | — | Trim |
| 25 | AVTX | Avalo Therapeutics Inc | +0.2% | +39.53% | Add |
| 26 | AMLX | Amylyx Pharmaceuticals Inc | +0.2% | +139.66% | Add |
| 27 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | — | Unchanged |
| 28 | CGON | Cg Oncology Inc | +0.2% | -14.84% | Trim |
| 29 | PRLD | Prelude Therapeutics Inc | +0.2% | — | Unchanged |
| 30 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 31 | ELVN | Enliven Therapeutics Inc | +0.1% | — | Unchanged |
| 32 | ARGX | Argenx Se - Adr | +0.1% | -17.16% | Trim |
| 33 | RPTX | Repare Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | RYTM | Rhythm Pharmaceuticals Inc | 0% | -13.42% | Trim |
| 35 | PMVP | Pmv Pharmaceuticals Inc | 0% | -7.72% | Trim |
| 36 | BIOA | Bioage Labs Inc | 0% | -14.22% | Trim |
| 37 | KRRO | Korro Bio Inc | 0% | — | Unchanged |
| 38 | QTTB | Q32 Bio Inc | 0% | — | Unchanged |
| 39 | CCCC | C4 Therapeutics Inc | 0% | -23.35% | Trim |
| 40 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 41 | WHWK | Whitehawk Therapeutics Inc | 0% | — | Unchanged |
| 42 | ANRO | Alto Neuroscience Inc | 0% | — | Unchanged |
| 43 | XERS | Xeris Biopharma Holdings Inc | 0% | — | Unchanged |
| 44 | TRAW | Traws Pharma Inc | — | — | Unchanged |
| 45 | INSM | Insmed Inc | — | — | Trim |
| 46 | 2KZ0 | Kezar Life Sciences Inc | — | — | Unchanged |
| 47 | ✓ | Dih Hldg US Inc | — | — | Unchanged |
| 48 | ✓ | Ikena Oncology Inc | 0% | -48.45% | Trim |
| 49 | NSPR | Inspiremd Inc | 0% | — | Unchanged |
| 50 | AVBP | Arrivent Biopharma Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 104 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BSX, EWTX, LLY) accounted for 20.2% of total reported equity market value during Q3 2025.
Top New Position Initiated
CAI
市值: $91.8M
Top Position Liquidated / Trimmed
UNH
前期市值: $105.4M
During Q3 2025, Orbimed Advisors LLC's top holdings by market value included BSX (6.0%)、EWTX (5.9%)、LLY (5.4%). The largest single position, BSX, represented 6.0% of total portfolio value.
In Q3 2025, Orbimed Advisors LLC made 113 total portfolio adjustments, initiating 32 new buys, adding to 18 positions, trimming 28 holdings, and fully liquidating 35 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.